Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 28;13(4):924-929.
doi: 10.3390/idr13040084.

COVID-19 Vaccine Booster: To Boost or Not to Boost

Rahul Shekhar  1 , Ishan Garg  2 , Suman Pal  1 , Saket Kottewar  3 , Abu Baker Sheikh  1
Affiliations
Review

COVID-19 Vaccine Booster: To Boost or Not to Boost

Rahul Shekhar et al. Infect Dis Rep. .

Abstract

Developing safe and effective vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at a breakneck speed has been an exceptional human achievement. It remains our best hope of containing the coronavirus disease 2019 (COVID-19) pandemic. However, newer, more aggressive SARS-CoV-2 viral strains, as well as the possibility of fading immunity following vaccination, have prompted health officials to investigate the necessity for additional immunization. This has put further pressure on disregarded human life in lower-income countries that already have minimal access to COVID-19 vaccines. The Centers for Disease Control and Prevention (CDC) have recommended a third COVID-19 vaccine dose in immunocompromised individuals in a recent announcement. Governments and health care officials need to develop usage guidelines for COVID-19 vaccine booster doses while considering the dangers of potential waning immunity and new viral strains and prioritizing vulnerable populations everywhere, including those living in lower-income countries.

Keywords: COVID-19; COVID-19 vaccines; booster; coronavirus 2019; immunocompromised; third dose; vaccine; vaccine inequity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. WHO WHO Coronavirus (COVID-19) [(accessed on 14 August 2021)]. Available online: https://covid19.who.int/
    1. FDA Emergency Use Authorization for Vaccines to Prevent COVID-19. [(accessed on 14 August 2021)]; Available online: https://www.fda.gov/regulatory-information/search-fda-guidance-documents....
    1. WHO WHO Validates Sinovac COVID-19 Vaccine for Emergency Use and Issues Interim Policy Recommendations. [(accessed on 14 August 2021)]. Available online: https://www.who.int/news/item/01-06-2021-who-validates-sinovac-covid-19-....
    1. Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1. - DOI - PMC - PubMed
    1. FDA FDA Approves First COVID-19 Vaccine. [(accessed on 27 August 2021)]; Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-first-c....

LinkOut - more resources